Phase 2 Oesophageal Cancer Trial, Recruiting NCT06675201 Sponsor: Sichuan University Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT06675201
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 80 years old
  • People who have been diagnosed with locally advanced, inoperable esophageal squamous cell cancer (a type of throat/food pipe cancer) and have already completed a full course of treatment aimed at curing the cancer (such as chemotherapy combined with radiation)
  • This includes people whose cancer is in a specific location or has spread to nearby lymph nodes, those for whom surgery was not successful or was refused, those whose cancer did not respond to pre-surgery treatment, or those whose cancer has come back in the same area after surgery and cannot be removed
  • People who showed no signs of the cancer returning or spreading when checked 2 to 3 weeks after completing their full course of treatment
  • People who are able to provide a fresh tissue sample from the tumor at the start of the trial
  • People whose heart, liver, kidneys, and other major organs are functioning normally
  • People who are in generally good physical condition, able to carry out everyday activities with little or no limitation (confirmed by a standard health score of 1 or less)
  • People who are able to have children and agree to use contraception during the trial
  • People who are willing to take part and have signed a consent form

Who may not be able to join:

  • People who have previously developed a fistula (an abnormal tunnel or opening in the body) caused by their cancer
  • People considered to be at high risk of serious bleeding in the digestive tract, or of developing a hole or abnormal opening in the food pipe
  • People who are in poor nutritional health
  • People who experienced serious immune-related side effects (such as severe lung inflammation or heart inflammation) during their previous cancer treatment
  • People who have signs or symptoms of interstitial disease (a group of conditions that affect the tissue and space around the organs, particularly the lungs — confirm with trial site)
  • People who have severe or uncontrolled health conditions of any kind
  • People who have another active cancer at the same time
  • People who have other autoimmune diseases (conditions where the immune system attacks the body), or who have been taking immune-suppressing medications or steroids for a long period of time
  • People who have difficulty communicating or who would be unable to attend regular long-term follow-up appointments
  • People the trial investigators consider unsuitable for other reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: zhenyu ding, MD, West China Hospital of Sichuan University, ChengDu, China

Phone: +86 028-854-22562

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Sichuan University
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
1 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

2-year OS rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov